Akyso
Akyso Therapeutics is a pharmaceutical company focused on advancing sustained release drug delivery systems, particularly for opioid use disorder. Their proprietary iSTEP technology enables safe, effective, and tunable extended-release drug implants that are bioabsorbable and designed for easy subcutaneous implantation. The company's mission is to improve treatment adherence and address the opioid epidemic with innovative drug delivery solutions.
Industries
Nr. of Employees
small (1-50)
Products
Subcutaneous bioabsorbable tunable extended‑release polymer implant for small-molecule APIs
A bioabsorbable polymer implant designed for subcutaneous placement that delivers small-molecule drugs over a sustained period (approximately six to twelve months) with tunable release via polymer composition adjustments.
Subcutaneous bioabsorbable tunable extended‑release polymer implant for small-molecule APIs
A bioabsorbable polymer implant designed for subcutaneous placement that delivers small-molecule drugs over a sustained period (approximately six to twelve months) with tunable release via polymer composition adjustments.
Services
Research and development of sustained‑release subcutaneous implants
Internal R&D capabilities covering formulation, in vitro release testing, preclinical in vivo studies, and device design for bioabsorbable subcutaneous implants.
Research and development of sustained‑release subcutaneous implants
Internal R&D capabilities covering formulation, in vitro release testing, preclinical in vivo studies, and device design for bioabsorbable subcutaneous implants.
Expertise Areas
- Implantable drug delivery
- Formulation development and CMC for sustained-release systems
- Preclinical in vitro and in vivo pharmacokinetics
- Toxicology and biocompatibility studies for IND support
Key Technologies
- Polymeric controlled-release implants
- Bioabsorbable polymer materials
- Subcutaneous implantable delivery systems
- In vitro release testing and PK profiling